The i-Technology Media!
Register | Log in
   
 
.NET  ·  AJAX  ·  CLOUD  ·  ECLIPSE  ·  FLEX  ·  OPEN WEB  ·  iPHONE  ·  JAVA  ·  LINUX  ·  OPEN SOURCE  ·  ORACLE  ·  PBDJ  ·  SEARCH  ·  SILVERLIGHT  ·  SOA  ·  VIRTUALIZATION  ·  WEB 2.0  ·  WIRELESS  ·  XML
Comments
Plone and Drupal: Different Approaches, Different Results
paul.nowak wrote: Matt, thanks for the comments. I made an error on the version of Plone. It's 2.5 Plone running on Zope 2.9x. In regards to the additional products, we have a skin installed and we have a product that we had custom developed for us that connects to a PostgreSQL database. We've looked at slow PostgreSQL queries causing problems and have not been able to find an issue. We've also tested for the case where the PostgreSQL server is down and have not been able to create an issue. We therefor...
Nov. 4, 2009 04:19 PM EST
Cloud Expo on Google News
Did you read today's front page stories & breaking news?


2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts

2009 East
GOLD SPONSORS:
CA
Get Your Transactions Under Control: SOA Performance Management
Software AG
Performance Driven Adoption: The Secret to Advancing SOA
Intel
The Evolving SOA Appliance: 3 Game-Changing Innovations
SILVER SPONSOR:
Denodo
Data Mashups: Deliver Your Project Faster with Virtualized Data Services Across Internal & External Sources
POWER PANELS:
The Business Value of Service Orientation
Driving Profitability Through User Experience
Click For 2008 West
Event Webcasts
Live Google News by SYS-CON!
Top Three Links You Must Click On


From the Wires
Amarillo Biosciences Issues Corporate Update on Influenza and Hepatitis C Research and Behcet's Disease and Oral Warts Phase 2 Trials
Amarillo Biosciences Issues Corporate Update on Influenza and Hepatitis C Research and Behcet's Disease and Oral Warts Phase 2 T

By: Marketwire .
May. 2, 2007 04:13 PM

AMARILLO, TX -- (MARKET WIRE) -- 05/02/07 -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today issued the following progress report on its influenza research, on plans for a study in 150 patients with hepatitis C, and on its Phase 2 clinical trials in Behcet's disease and oral warts in HIV positive patients. The Company also provided information on its forthcoming Annual Meeting.

Influenza Research

Working in collaboration with ABI, Australian and United States researchers conducted a number of studies over the past 15 months exploring the efficacy of low-dose oral interferon against mouse-adapted influenza virus. A leading German research institute has continued this research the past six weeks, challenging laboratory mice with varying doses of an avian influenza strain known as fowl plague virus. Preliminary findings have shown that low-dose oral interferon provides a significant survival benefit against a fatal challenge of this virus. Moreover, when a less-than-fatal dose of the virus was introduced in mice, treatment with oral interferon (compared to placebo) resulted in less weight loss and fewer signs of disease. More work to confirm these findings will be carried out in Germany and Australia in coming weeks. ABI plans to present results of these studies -- along with data from other animal research in Australia, Europe and the U.S. -- as part of its campaign to gain consideration of oral interferon therapy in the debate over how best to cope with a potential flu pandemic.

Hepatitis C Study in Taiwan

In November 2006, CytoPharm, Inc, a Taipei, Taiwan-based biopharmaceutical company, entered into a license and supply agreement with ABI. Under terms of that agreement, CytoPharm has selected hepatitis C as the focus of its first human clinical study. The company earlier had licensed the clinical indications of influenza and hepatitis B. CytoPharm told ABI it hopes to begin enrollment in the 150 patient study of low-dose oral interferon in the fourth quarter of 2007. Current standard therapy for hepatitis C is usually high-dose injectable interferon and ribavirin. Low-dose oral interferon would represent a less toxic and more affordable alternative.

Behcet's Disease Study Adds Two New Sites in Turkey

In an effort to accelerate the completion of its Phase 2 clinical trial on Behcet's disease, an autoimmune disorder, Nobel Ilac Sanayii Ve Ticaret A.S., ABI's Middle Eastern partner, expects to start enrollment this month of Behcet's disease patients at two new clinical sites in Turkey. Nobel has enrolled 62 patients to date, and expects to achieve the full 90-patient enrollment by September. The study is targeted for completion by year-end 2007.

The double-blinded Phase 2 study is testing the efficacy of interferon lozenges versus placebo in the treatment and prevention of mouth ulcers suffered by virtually all Behcet's disease patients. ABI's non-toxic oral interferon represents a significant potential improvement over corticosteroids and other treatment products, which have significant side effects.

Enrollment in Phase 2 Clinical Trial of Oral Warts in HIV+ Patients

Three more clinical sites -- in Philadelphia, Fort Lauderdale and Newark -- have agreed to join the six previously announced sites approved to enroll patients in a study of HIV+ patients suffering from oral warts, a papillomavirus infection. This placebo-controlled Phase 2 study is a follow-up to two successful studies that have already completed. In the latest study, 57% of HIV+ patients given the optimum dose of oral interferon experienced complete or near complete clearance of their oral warts. As of May 1, 2007, 10 of 80 planned subjects had been enrolled in the new study; complete enrollment is expected by year-end. No products are currently approved by the FDA for this condition, so treatment of oral warts represents a unique market for ABI.

Separately, Amarillo Biosciences announced that its annual shareholders' meeting will be held at 7 p.m. CDT on Friday, June 1, 2007, at the Ambassador Hotel, 3100 I-40 West, in Amarillo, Texas.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 13% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for oral interferon therapies. Additional information is available on the ABI web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2006.

Investor Relations:
Philippe Niemetz
PAN Consultants, Ltd.
email: Email Contact
Tel: 800-477-7570
212-344-6464
Fax: 212-618-1276

Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
email: Email Contact
Tel: 806-376-1741 x 13
Fax: 806-376-9301

Published May. 2, 2007
Copyright © 2007 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.
About Marketwire .
Copyright © 2009 Marketwire. All rights reserved. All the news releases provided by Market Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021

SYS-CON Featured Whitepapers

ADS BY GOOGLE

Breaking Java News
Pragma Securities Chooses Switch and Data’s New York Financial EcoCenterSM to Optimize the Performance of its Quantitative Trading Solutions
Transaction Wireless Signs Bass Pro Shops for wGiftCard Mobile Gift Card Solutions
Avail-TVN Goes Long with NFL Network Deal
Wall Street News Alert: Tuesday's Stock Highlight: PrimeGen Energy - November 9, 2009
Chipworks Selects SensorDynamics Combisensor – Product of the Year 2009
RGB Networks Demonstrates Advanced Transcoding Capabilities of its Video Processing Platform at TelcoTV 2009
Seoul Korea’s Subway System to Deploy World’s First Real-Time, Mobile Wireless Video Surveillance Networked by Firetide
Syncplicity Launches Integrated Business Service with Robust Sync, Backup, Collaboration and File Management
Breach Security Executive to Present on Web Application Security Tools and Trends at OWASP AppSec DC 2009
OAISYS Tracer Delivers Affordable, Enterprise-Class Quality Assurance and Workforce Optimization

ADVERTISE   |   MAGAZINE SUBSCRIPTIONS   |   FREE BREAKING-NEWSLETTERS!   |   SYS-CON.TV   |   BLOG-N-PLAY!   |   WEBCAST   |   EDUCATION   |   RESEARCH

.NET Developer's Journal - .NETDJ   |   ColdFusion Developer's Journal - CFDJ   |   Eclipse Developer's Journal - EDJ   |   Enterprise Open Source Magazine - EOS
Open Web Developer's Journal - OPENWEB   |   iPhone Developer's Journal - iPHONE   |   Virtualization - Virtualization   |   Java Developer's Journal - JDJ   |   Linux.SYS-CON.com
PowerBuilder Developer's Journal - PBDJ   |   SEO / SEM Journal - SJ   |   SOAWorld Magazine - SOAWM   |   IT Solutions Guide - ITSG   |   Symbian Developer's Journal - SDJ
WebLogic Developer's Journal - WLDJ   |   WebSphere Journal - WJ   |   Wireless Business & Technology - WBT   |   XML-Journal - XMLJ   |   Internet Video - iTV
Flex Developer's Journal - Flex   |   AJAXWorld Magazine - AWM   |   Silverlight Developer's Journal - SLDJ   |   PHP.SYS-CON.com   |   Web 2.0 Journal - WEB2
Apache   |   CMS   |   CRM   |   HP   |   Oracle Journal   |   Perl   |   Python   |   Red Hat   |   Ruby on Rails   |   SAP   |   SaaS

SYS-CON MEDIA:   ABOUT US   |   CONTACT US   |   COMPANY NEWS   |   CAREERS   |   SITE MAP
SYS-CON EVENTS:   |  AJAXWorld Conference & Expo  |  iPhone Developer Summit  |  Cloud Computing Conference & Expo  |  SOA World Conference & Expo  |  Virtualization Conference & Expo
INTERNATIONAL SITES:   India  |  U.K.  |  Canada  |  Germany  |  France  |  Australia  |  Italy  |  Spain  |  Netherlands  |  Brazil  |  Belgium
 Terms of Use & Our Privacy Statement     About Newsfeeds / Video Feeds
Copyright ©1994-2008 SYS-CON Publications, Inc. All Rights Reserved. All marks are trademarks of SYS-CON Media.
Reproduction in whole or in part in any form or medium without express written permission of SYS-CON Publications, Inc. is prohibited.
 
close this window